Daily Nutritional Supplementation with Vitamin D3 and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial
Open Access
- 10 January 2019
- Vol. 11 (1), 133
- https://doi.org/10.3390/nu11010133
Abstract
Poor nutritional status is common among human immunodeficiency virus (HIV)-infected patients including vitamin D (vitD3) deficiency. We conducted a double-blinded, randomized, and placebo-controlled trial in Addis Ababa, Ethiopia, to investigate if daily nutritional supplementation with vitD3 (5000 IU) and phenylbutyrate (PBA, 2 × 500 mg) could mediate beneficial effects in treatment-naïve HIV patients. Primary endpoint: the change in plasma HIV-1 comparing week 0 to 16 using modified intention-to-treat (mITT, n = 197) and per-protocol (n = 173) analyses. Secondary endpoints: longitudinal HIV viral load, T cell counts, body mass index (BMI), middle-upper-arm circumference (MUAC), and 25(OH)D3 levels in plasma. Baseline characteristics were detectable viral loads (median 7897 copies/mL), low CD4+ (median 410 cells/µL), and elevated CD8+ (median 930 cells/µL) T cell counts. Most subjects were vitD3 deficient at enrolment, but a gradual and significant improvement of vitD3 status was demonstrated in the vitD3 + PBA group compared with placebo (p < 0.0001) from week 0 to 16 (median 37.5 versus 115.5 nmol/L). No significant changes in HIV viral load, CD4+ or CD8+ T cell counts, BMI or MUAC could be detected. Clinical adverse events were similar in both groups. Daily vitD3 + PBA for 16 weeks was well-tolerated and effectively improved vitD3 status but did not reduce viral load, restore peripheral T cell counts or improve BMI or MUAC in HIV patients with slow progressive disease. Clinicaltrials.gov NCT01702974.Keywords
Funding Information
- Vetenskapsrådet (K2015-56X-20665-08-3)
- Myndigheten för Samhällsskydd och Beredskap (2010-7938)
- Karolinska Institutet (senior research position for SB)
- Merck KGaA (provided study drugs (Vigantoletten))
This publication has 58 references indexed in Scilit:
- Associations between 25-Hydroxyvitamin D and Immunologic, Metabolic, Inflammatory Markers in Treatment-Naive HIV-Infected Persons: The ANRS CO9 «COPANA» Cohort StudyPLOS ONE, 2013
- Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral TherapyNew England Journal of Medicine, 2013
- Short-Course Antiretroviral Therapy in Primary HIV InfectionNew England Journal of Medicine, 2013
- Vitamin D Inhibits Human Immunodeficiency Virus Type 1 and Mycobacterium tuberculosis Infection in Macrophages through the Induction of AutophagyPLoS Pathogens, 2012
- Vitamin D Status and its Association with Morbidity Including Wasting and Opportunistic Illnesses in HIV-Infected Women in TanzaniaAIDS Patient Care and STDs, 2011
- Vitamin D and the anti-viral stateJournal of Clinical Virology, 2011
- Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progressionJournal of General Virology, 2010
- Vitamin D Status of HIV-Infected Women and Its Association with HIV Disease Progression, Anemia, and MortalityPLOS ONE, 2010
- Predictors of disease progression in HIV infection: a reviewAIDS Research and Therapy, 2007
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002